A5000243266- Acute Myeloid Leukemia Research
- Acute Lymphoblastic Leukemia research
- Chronic Myeloid Leukemia Treatments
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Chronic Lymphocytic Leukemia Research
- Hematopoietic Stem Cell Transplantation
- CAR-T cell therapy research
- Lymphoma Diagnosis and Treatment
- Neutropenia and Cancer Infections
- Histone Deacetylase Inhibitors Research
- Multiple Myeloma Research and Treatments
- Protein Degradation and Inhibitors
- Childhood Cancer Survivors' Quality of Life
- Eosinophilic Disorders and Syndromes
- Monoclonal and Polyclonal Antibodies Research
- Viral-associated cancers and disorders
- Retinoids in leukemia and cellular processes
- Hematological disorders and diagnostics
- Immune Cell Function and Interaction
- Lung Cancer Treatments and Mutations
- CNS Lymphoma Diagnosis and Treatment
- Radiopharmaceutical Chemistry and Applications
- Cutaneous lymphoproliferative disorders research
- Epigenetics and DNA Methylation
- Renal Transplantation Outcomes and Treatments
Medical College of Wisconsin
2016-2025
Froedtert Hospital
2025
Dana-Farber Cancer Institute
2022
Palmetto Hematology Oncology
2020
Spartan Health Sciences University
2020
University of Arkansas for Medical Sciences
2013-2017
Post Graduate Institute of Medical Education and Research
2012-2015
Virginia Commonwealth University Medical Center
1966
Matched sibling donors (MSDs) are preferred for allogeneic hematopoietic cell transplantation (allo-HCT) in myelodysplastic syndrome even if they older. However, whether older MSDs or younger human leukocyte antigen-matched unrelated (MUDs) associated with better outcomes remains unclear.To investigate allo-HCT using MUDs would be improved disease-free survival and less relapse compared MSDs.This retrospective cohort study assessed data reported to the Center International Blood Marrow...
Allogeneic stem cell transplant (alloHCT) is considered for all patients with myeloid neoplasms (MN) harboring TP53-mutations (TP53mut). The aim of this international study across 7 centers in USA and Australia was to identify factors associated improved post-alloHCT survival. Of 134 TP53mut MN cases who underwent alloHCT, 80% harbored complex karyotype (CK); 94% TP53 variants were localized the DNA-binding domain (DBD). Most common co-mutations ASXL1 (7%), TET2 DNMT3A (6%). Median post-HCT...
Allogeneic hematopoietic cell transplantation (allo-HCT) remains the only curative treatment for myelofibrosis. However, optimal conditioning regimen either with reduced-intensity (RIC) or myeloablative (MAC) is not well known. Using Center International Blood and Marrow Transplant Research database, we identified adults aged ≥18 years myelofibrosis undergoing allo-HCT between 2008-2019 analyzed outcomes separately in RIC MAC cohorts based on regimens used. Among 872 eligible patients, 493...
Progression of myeloproliferative neoplasms (MPNs) to accelerated or blast phase is associated with poor survival outcomes. Since 2017 there have been several therapies approved for use in acute myeloid leukemia (AML); these incorporated into the management accelerated/blast-phase MPNs (MPN-AP/BP). We performed a multicenter analysis investigate outcomes patients diagnosed MPN-AP/BP later. In total, 202 were identified; median overall (OS) was 0.86 years. also analyzed based on first-line...
Abstract Venetoclax (VEN) combined with hypomethylating agents (HMAs) is the standard of care for treatment patients newly diagnosed acute myeloid leukemia (AML) unfit intensive chemotherapy. To date, real‐world data published on HMAs plus VEN have been either single‐center studies or using community‐based electronic databases limited details mutational landscape, tolerability, and patterns in elderly patients. Therefore, we conducted a multicenter retrospective study to assess experience...
Abstract Recent studies demonstrating the feasibility of outpatient chimeric antigen receptor (CAR)–modified T-cell therapy administration are either restricted to CARs with 41BB costimulatory domains or use intensive at-home monitoring. We report outcomes all commercially available CD19- and B-cell maturation (BCMA)–directed CAR using a strategy no remote monitoring an early cytokine release syndrome (CRS) intervention strategy. Patients hematologic malignancies who received in setting...
We examined the impact of vancomycin-resistant Enterococcus (VRE) bloodstream infection (BSI) on outcomes allogeneic hematopoietic cell transplantation (HCT) utilizing Center for International Blood and Marrow Transplant Research database.Adult pediatric patients (N = 7128) who underwent first HCT acute leukemia or myelodysplastic syndrome from 2008 through 2012 were analyzed as 3 groups-VRE BSI, non-VRE without BSI-according to BSI status at 100 days (D100) after HCT. Multivariable models...
Abstract Allogeneic hematopoietic cell transplantation (allo‐HCT) is a potentially curative treatment for acute myeloid leukemia (AML) and lymphoblastic (ALL). While many factors influence the outcomes of allo‐HCT, independent impact donor–recipient ABO mismatching remains unclear. Using Center International Blood Marrow Transplant Research (CIBMTR) database, we identified patients aged ≥18 years with AML or ALL who underwent allo‐HCT between 2008 2018. Our objectives were to analyze based...
Azacitidine/venetoclax is an active regimen in patients with newly diagnosed AML. However, primary or secondary resistance to azacitidine/venetoclax area of unmet need and overexpression MCL-1 suggested be a potential mechanism. Pevonedistat inhibits through activation NOXA, pevonedistat/azacitidine has previously shown activity To assess the tolerability efficacy adding pevonedistat relapsed/refractory AML, we conducted phase I multicenter openlabel study 16 adults Patients were treated...
Chronic myelomonocytic leukemia (CMML) is an aggressive neoplasm with sparse data on outcomes at a population level. Using Surveillance Epidemiology and End Results (SEER) database, we identified 2238 patients CMML diagnosed in the period 2003–2013. We found that disease incidence was significantly higher advancing age lower females, Blacks, Asian/pacific islanders. Median OS declined increasing (age 20–39 – 25 months, 40–59 20 60–79 18 ≥80 11 p < .01), but did not vary by gender or race....
Allogeneic hematopoietic cell transplantation (alloHCT) provides cure for older patients with acute myeloid leukemia (AML); however, disease relapse remains a major concern. Based on recent data suggesting that younger donor age confers the greatest benefit alloHCT matched unrelated donors (MUDs), we attempted to answer practical question: which type best outcomes when an patient AML has sibling (MSD, also older) versus MUD? This retrospective cohort registry study accessed from Center...
Core-binding factor acute myeloid leukemia (CBF-AML) is characterized by the presence of inv(16)/t(16;16) or t(8;21) and classified as a favorable risk 2022 European LeukemiaNet (ELN) guidelines. The CD33-targeting antibody-drug conjugate, gemtuzumab ozogamicin (GO), commonly added to intensive chemotherapy (IC) in CBF-AML. We sought compare outcomes patients treated with IC without GO included 200 CBF-AML across seven academic centers. Induction treatment regimens were categorized alone,...
T-cell acute lymphoblastic leukemia (T-ALL) is a curable malignancy in the pediatric population. However, population-level data on its incidence and outcomes among adults sparse. Using SEER database, we identified 1141 patients aged ≥20 years with pathologically confirmed T-ALL diagnosed between 2001 2014 actively followed. Incidence of was 0.13 cases/100,000 population significant variations by age, gender, race, period. The 5-year overall survival (OS) declined significantly increasing age...
While there is clear evidence to suggest poorer outcome associated with multi-hit (MH) TP53 mutation (TP53MT) compared a single-hit (SH) in lower-risk myelodysplastic syndrome (MDS), data are conflicting both higher-risk MDS and acute myeloid leukemia (AML). We conducted an in-depth analysis utilizing from ten US academic institutions study differences molecular characteristics outcomes of SH (N=139) versus MH (N=243) TP53MT AML. Complex cytogenetics were more common than AML (P<0.001);...
ABSTRACT Introduction This phase 2 study evaluated magrolimab+venetoclax (VEN)+azacitidine (AZA) in untreated, unfit acute myeloid leukaemia (AML) and magrolimab+mitoxantrone+etoposide+cytarabine relapsed/refractory (R/R) AML. Methods Endpoints included complete remission rate (CRR), overall response (ORR), survival (OS) safety. Results Eighteen 36 patients were enrolled into the R/R AML arms, respectively. CRR was 38.9% 25.0%, ORR 66.7% 38.9%, median OS 15.3 10.5 months No dose‐limiting...
Allogeneic hematopoietic cell transplantation (allo-HCT) with reduced-intensity conditioning (RIC) is commonly performed as an inpatient procedure. The feasibility and outcomes of RIC allo-HCT in the outpatient setting not known. We a single-center retrospective cohort study patients aged ≥ 18years hematologic malignancies who underwent either or setting. Donor types included HLA-matched sibling well-matched unrelated donors. objectives were to compare survival, complications, charges,...
Background Outcomes of acute promyelocytic leukemia (APL) have significantly improved with the availability targeted agents. It remains unclear whether population-level outcomes APL over time. Methods Using SEER database, we identified patients aged ≥20 years pathologically confirmed diagnosed in 2000 through 2014 and who were actively followed. Patients stratified by diagnosis period into 3 groups (2000-2004, 2005-2009, 2010-2014) to assess temporal trends overall survival (OS),...